Servier deepens commitment in India by establishing a platform dedicated to Single Pill Combinations in Cardiometabolism and Venous Diseases

 A model of Indo–French collaboration to deliver high-quality therapies

 Investing around €15 million euro in 2026 to set up a platform and work with Indian partners to develop top quality Single Pill Combinations (SPCs) to be exported from India to several countries where the unmet need of patient adherence is high. 

*Mumbai, February 11, 2026:* Servier, the independent French pharmaceutical group governed by a foundation, has announced the establishment of a global platform in India - *‘GATINN’* - to work with partners to develop, manufacture and export *Single Pill Combinations (SPCs)*  for cardiometabolic and venous diseases. The platform aims to improve adherence and enable better long-term outcomes for patients globally by simplifying treatment regimens through SPCs. The initiative reflects Servier’s 2030 ambition to accelerate innovation and deliver patient-centric solutions, particularly in chronic conditions where treatment adherence remains a critical challenge. 

*Elaborating on this, Dr. Kshitij Panse, Chief Operating Officer - GATINN, said,* “GATINN embodies Servier’s strategy to address critical patient unmet needs by accelerating patient-centric innovation. ‘GATI’ signifies speed, reflecting our focus on rapidly delivering solutions, while ‘INN’ represents innovation in India. By combining a dedicated local team, carefully selected partners, and Servier’s global R&D, manufacturing, and quality expertise, we are building a platform to execute high-quality SPCs that meet global standards and help improve adherence and outcomes for patients worldwide.”

Servier plans to invest approximately €15 million in 2026 in GATINN, working closely with Indian partners to bring high-quality, differentiated SPCs to patients. The GATINN platform integrates development, manufacturing, supply chain and quality oversight under a single India-based coordination hub. Manufacturing is carried out through selected Indian CDMO partners, while active pharmaceutical ingredients continue to be sourced from Servier’s production facilities where Servier is the originator. 

This approach demonstrates a pragmatic model of Indo–French collaboration combining French R&D expertise with India’s proven development and manufacturing quality and operational agility, enabling Servier to deliver high-quality therapies with speed, cost-efficiency to multiple international markets in Asia, Latin America, Africa, and the Middle East regions.

Speaking about the platform, *Ms. Charlotte Marmousez, Executive Vice President Corporate Strategy & Transformation, said,* “The decision to establish GATINN in India aligns with Servier’s global strategy to advance patient-centered innovation by developing top quality SPCs to improve patient adherence. This is first such platform for Servier, which will coordinate on behalf of the global Servier teams from research and manufacturing, based in the headquarters in France.”

Few projects have already been initiated with the *first international launch expected in Q2 2027* . The platform is expected to have around 5 products in development by the end of 2026, followed by the addition of approximately one new SPC each year till 2030—thereby establishing a steady pipeline of SPCs